Literature DB >> 12476300

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.

Brian J Druker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12476300     DOI： 10.1038/sj.onc.1206081

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


× No keyword cloud information.
  26 in total

1.  S-glutathionylated serine proteinase inhibitors as plasma biomarkers in assessing response to redox-modulating drugs.

Authors:  Christina L Grek; Danyelle M Townsend; Joachim D Uys; Yefim Manevich; Woodrow J Coker; Christopher J Pazoles; Kenneth D Tew
Journal:  Cancer Res       Date:  2012-03-08       Impact factor: 12.701

Review 2.  Mechanisms leading to nonrandom, nonhomologous chromosomal translocations in leukemia.

Authors:  Susanne M Gollin
Journal:  Semin Cancer Biol       Date:  2006-10-26       Impact factor: 15.707

3.  Specific killing of Rb mutant cancer cells by inactivating TSC2.

Authors:  Binghui Li; Gabriel M Gordon; Charles H Du; Jinhua Xu; Wei Du
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

4.  American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.

Authors:  Jeffrey S Weber; Laura A Levit; Peter C Adamson; Suanna Bruinooge; Howard A Burris; Michael A Carducci; Adam P Dicker; Mithat Gönen; Stephen M Keefe; Michael A Postow; Michael A Thompson; David M Waterhouse; Susan L Weiner; Lynn M Schuchter
Journal:  J Clin Oncol       Date:  2014-12-15       Impact factor: 44.544

5.  A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia.

Authors:  Ji Hoon Jung; Miyong Yun; Eun-Jeong Choo; Sun-Hee Kim; Myoung-Seok Jeong; Deok-Beom Jung; Hyemin Lee; Eun-Ok Kim; Nobuo Kato; Bonglee Kim; Sanjay K Srivastava; Kunihiro Kaihatsu; Sung-Hoon Kim
Journal:  Br J Pharmacol       Date:  2015-06-04       Impact factor: 8.739

6.  Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.

Authors:  Boyka Markova; Patricia S Hähnel; Stefan Kasper; Stephan Herbertz; Martin Schuler; Frank Breitenbuecher
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-28       Impact factor: 4.553

7.  Repositioning antispasmodic drug Papaverine for the treatment of chronic myeloid leukemia.

Authors:  Phani Krishna Parcha; Sailu Sarvagalla; Cheemala Ashok; S J Sudharshan; Madhu Dyavaiah; Mohane Selvaraj Coumar; Baskaran Rajasekaran
Journal:  Pharmacol Rep       Date:  2021-01-03       Impact factor: 3.024

8.  Kinase impact assessment in the landscape of fusion genes that retain kinase domains: a pan-cancer study.

Authors:  Pora Kim; Peilin Jia; Zhongming Zhao
Journal:  Brief Bioinform       Date:  2018-05-01       Impact factor: 11.622

9.  Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.

Authors:  M Golam Mohi; Christina Boulton; Ting-Lei Gu; David W Sternberg; Donna Neuberg; James D Griffin; D Gary Gilliland; Benjamin G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

10.  Principles of cancer therapy: oncogene and non-oncogene addiction.

Authors:  Ji Luo; Nicole L Solimini; Stephen J Elledge
Journal:  Cell       Date:  2009-03-06       Impact factor: 41.582
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.